Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;48(3):1042-1062.
doi: 10.1007/s10753-024-02125-z. Epub 2024 Aug 20.

MicroRNAs Modulating Neuroinflammation in Parkinson's disease

Affiliations
Review

MicroRNAs Modulating Neuroinflammation in Parkinson's disease

Mohamed J Saadh et al. Inflammation. 2025 Jun.

Abstract

Parkinson's disease (PD) is one of the most frequent age-associated neurodegenerative disorder. Presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc) and loss of dopaminergic (DA) neurons are among the characteristic of PD. One of the hallmarks of PD pathophysiology is chronic neuroinflammation. Activation of glial cells and elevated levels of pro-inflammatory factors are confirmed as frequent features of the PD brain. Chronic secretion of pro-inflammatory cytokines by activated astrocytes and microglia exacerbates DA neuron degeneration in the SNpc. MicroRNAs (miRNAs) are among endogenous non-coding small RNA with the ability to perform post-transcriptional regulation in target genes. In that regard, the capability of miRNAs for modulating inflammatory signaling is the center of attention in many investigations. MiRNAs could enhance or limit inflammatory signaling, exacerbating or ameliorating the pathological consequences of extreme neuroinflammation. This review summarizes the importance of inflammation in the pathophysiology of PD. Besides, we discuss the role of miRNAs in promoting or protecting neural cell injury in the PD model by controlling the inflammatory pathway. Modifying the neuroinflammation by miRNAs could be considered a primary therapeutic strategy for PD.

Keywords: Inflammation; MiRNA; Non-coding RNA; Nondegenerative Diseases; Parkinson’s disease.

PubMed Disclaimer

Conflict of interest statement

Declarations. COMPETING OF INTEREST: The authors declare no competing interests.

Similar articles

Cited by

References

    1. Waak, J., S.S. Weber, A. Waldenmaier, K. Görner, M. Alunni-Fabbroni, H. Schell, et al. 2009. Regulation of astrocyte inflammatory responses by the Parkinson’s disease-associated gene DJ–1. The FASEB Journal. 23 (8): 2478–2489. - PubMed - DOI
    1. Wirdefeldt, K., H.-O. Adami, P. Cole, D. Trichopoulos, and J. Mandel. 2011. Epidemiology and etiology of Parkinson’s disease: A review of the evidence. European Journal of Epidemiology. 26: 1–58. - DOI
    1. Fahn, S. 2003. Description of Parkinson’s disease as a clinical syndrome. Annals of the New York Academy of Sciences. 991 (1): 1–14. - PubMed - DOI
    1. Mori, F., Y.-S. Piao, S. Hayashi, H. Fujiwara, M. Hasegawa, M. Yoshimoto, et al. 2003. α-Synuclein accumulates in Purkinje cells in Lewy body disease but not in multiple system atrophy. Journal of Neuropathology & Experimental Neurology. 62 (8): 812–819. - DOI
    1. Surguchov, A., and A. Surguchev. 2022. Synucleins: New Data on Misfolding, Aggregation and Role in Diseases. Biomedicines 10 (12): 3241. - PubMed - PMC - DOI

LinkOut - more resources